We are pleased to announce the release of ChemDraw v25.0 and the latest updates to ChemDraw Prime, Professional & Signals ChemDraw. This release delivers several key enhancements that support the drawing and representation of large molecules and complementary strands as well as significant usability updates in the web editing experience offered with Signals ChemDraw.
What's New in ChemDraw
ChemDraw Desktop v25.0 Updates
Available in all offerings: ChemDraw Prime, ChemDraw Professional & Signals ChemDraw
Enhanced Chemical Intelligence
- Unified handling of coordination and dative bonds
- Updated stereochemistry labeling of allenes and atropisomers (R/S -> M/P)
Installation and System Improvements
- Streamlined installation with combined all user/current user options and improved installer behavior
- ChemDraw is now available for ARM Macs and Intel Macs
Available in ChemDraw Professional & Signals ChemDraw
ChemDraw Installers
- Two installers are now provided: ChemDraw and ChemDraw Applications
Advanced Biopolymer (HELM) Improvements
- Improved visualization and clean-up of biopolymers
- Curved connections between biopolymer sequences for improved visual clarity
- Flexible line wrapping options for biopolymer display
- Hydrogen bonds can be drawn between complementary DNA/RNA strands
- Support for atom-mapped SMILES in HELM strings, HELM in-line annotations & Genbank FASTA ChemDraw+
Exclusive to Signals ChemDraw offering and released continuously throughout the year in the Signals Platform, ChemDraw+ is a cloud-native version of ChemDraw allowing you to create, manage and curate your drawings in the web.
New Modern Drawing Experience
- Comprehensively redesigned drawing editor
- Advanced navigation with panning, scrolling, and precision zoom controls
- New Properties, Query & Guided Stereo panels for efficient structure editing
- New tools added including : 3D structure cleanup/perspective tools, Flip & rotate tools, access to common symbols used in chemical reactions, Enhanced stereo annotation tool
Advanced Biopolymer (HELM) Improvements
- Comprehensive support for the creation of duplexes with hydrogen bonding according to Watson-Crick base pairing via : manually drawing hydrogen bonds between strands, generating complementary strands via text tab, 'Generate Complement’ tool upon selection of a single RNA/DNA
- Pair two complementary strands with HELM ‘Auto-pair’ tool
- Improved visualization and clean-up of biopolymers
- Add crosslinks between monomers with multiple possible attachment points
- Add Sense/antisense annotations and in-line annotations to biopolymers
- Add 3'/5' end labeling to oligonucleotides
- BILN format support for peptides
- HELM hotkeys for editing biopolymers with editing/navigation improvements
Expanded Application Capabilities
- Structure based searching of drawings
- Upload multiple drawings
- Trash/Restore Notebooks
- Enhanced collaboration : sharing of Notebooks and Drawings, notifications of shared content
HELM Monomer Curation Application
Exclusive to Signals ChemDraw offering and released continuously throughout the year with the Signals Platform
- Single monomers can now be added to custom monomer libraries via the ‘New Monomer’ form For more information on any of the new features highlighted here, please visit the Signals ChemDraw What’s New website, which provides details of each ChemDraw release.
Product Compatibility
ChemDraw v25.0 is qualified against the following:
- Windows 10 (64-bit) and Windows 11 (64-bit)
- Microsoft Office 2021, Microsoft Office 2024, and Microsoft Office 365
- macOS 14.7 (Sonoma) and 15.5 (Sequoia) – (for ChemDraw only)
- Adobe Acrobat DC
ChemDraw Prime and Professional are available through the Revvity Signals Download Center. If you do not have access to the Download Center, contact Revvity Signals Support to assist you with sign-up.
Signals ChemDraw is available through the Signals Research Platform with an active license. Please contact your Account Manager if you are interested in purchasing.
https://revvitysignals.com/products/research/signals-chemdraw
Comments
0 comments
Article is closed for comments.